Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
U.S. FDA approves AstraZeneca's Tagrisso-chemo combo
10:44pm, Friday, 16'th Feb 2024
A combination of AstraZeneca's blockbuster cancer drug Tagrisso with chemotherapy to treat a type of lung cancer has been approved by the U.S. Food and Drug Administration (FDA), the company said in a
7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution
02:43pm, Wednesday, 14'th Feb 2024
It is entirely fair to state that weight loss treatments have massive transformational power. US FDA approval of weight loss medicines could help shrink millions of waistlines.
3 Stocks at 52-Week Lows to Buy Before They Rebound
01:52pm, Monday, 12'th Feb 2024
Finding good, bargain-priced stocks is difficult in a market regularly hitting new all-time highs. Although you can buy many cheap stocks, they are cheap for a reason.
AstraZeneca slides as argument continues to surround results
10:32am, Monday, 12'th Feb 2024
AstraZeneca PLC (LSE:AZN) was among the FTSE 100's big fallers on Monday as debate raged on around the company's year-end earnings late last week. AstraZeneca found itself still reeling from what the
AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on It
10:00am, Monday, 12'th Feb 2024
Zacks.com users have recently been watching Astrazeneca (AZN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
AstraZeneca downgraded as analysts highlight ‘underwhelming' year end
11:09am, Friday, 09'th Feb 2024
AstraZeneca PLC (LSE:AZN) faced a blow on Friday after Deutsche Bank analysts downgraded the pharmaceuticals giant on what they labelled a “thoroughly disappointing” end to 2023. Analysts wrote i
Astrazeneca (AZN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
04:01pm, Thursday, 08'th Feb 2024
Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall S
AstraZeneca PLC (AZN) Q4 2023 Earnings Call Transcript
03:10pm, Thursday, 08'th Feb 2024
AstraZeneca PLC (AZN) Q4 2023 Earnings Call Transcript
AstraZeneca Revenue Hurt as Demand for COVID-19 Treatments Slumps; Stock Drops
02:10pm, Thursday, 08'th Feb 2024
AstraZeneca PLC's (AZN) American depositary receipts (ADRs) fell more than 4% Thursday after the drug maker reported its profit was hurt by falling demand for COVID-19 treatments.
Jobless Claims Decreased More Than Expected
11:51am, Thursday, 08'th Feb 2024
This being Thursday morning, we see new Weekly Jobless Claims data ahead of the opening bell for trading. Initial Jobless Claims came in 2000 lower than projections to 218K, down 9K claims from the up
Jobless Claims Steady; Mixed Q4 for AZN, HSY and PM
11:35am, Thursday, 08'th Feb 2024
We're once again reassured that employment, on a finer week-over-week scale, is not falling off a cliff.
AstraZeneca Slips as Earnings, Cancer Drug Sales Disappoint
10:22am, Thursday, 08'th Feb 2024
Deutsche Bank also cut its rating of the stock to Sell from Buy.
AstraZeneca Earnings Hit By Higher Costs
03:39am, Thursday, 08'th Feb 2024
AstraZeneca reported core earnings for the fourth quarter just short of consensus, but said it expected double-digit percentage growth in 2024.
AstraZeneca sees £2.8bn knocked off its value amid cost concerns
03:26am, Thursday, 08'th Feb 2024
AstraZeneca PLC (LSE:AZN) shares fell 1.8%, wiping £2.8 billion from the value of the business, as lingering concerns on the drug maker's cost base overshadowed better than expected results and stro
